Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jan 11

PMID 38201636

Authors

Christos Damaskos

Iason Psilopatis

Anna Garmpi

Dimitrios Dimitroulis

Konstantinos Nikolettos

Kleio Vrettou

Panagiotis Sarantis

Evangelos Koustas

Gregory Kouraklis

Efstathios A Antoniou

Michail V Karamouzis

Nikolaos Nikolettos

Panagiotis Tsikouras

Georgios Marinos

Emmanouil Kontomanolis

Konstantinos Kontzoglou

Nikolaos Garmpis

Affiliations

Soon will be listed here.

Abstract

Background/aim: Triple negative breast cancer belongs to the most aggressive breast cancer forms. Histone deacetylases (HDACs) constitute a class of enzymes that exhibit a significant role in breast cancer genesis and progression. In this study, we aimed at assessing the clinical importance of HDAC-2 in triple negative breast cancer.

Materials And Methods: A total of 138 breast cancer specimens were examined on an immunohistochemical basis. A statistical analysis was performed in order to examine the association between HDAC-2 and the survival and clinicopathological features of the patients.

Results: Increased HDAC-2 expression was observed in every fourth case of triple negative breast cancer with positive HDAC-2 staining, whereas only 12 out of 98 non-triple negative breast cancer samples showed high HDAC-2 expression. HDAC-2 overexpression correlated with prolonged overall survival (OS) and disease-free survival (DFS) in triple negative breast cancer.

Conclusions: High HDAC-2 levels in triple negative breast cancer seem to positively influence patient survival, disease stage and recurrence.

Citing Articles

Dissecting the epigenetic orchestra of HDAC isoforms in breast cancer development: a review.

Debbarma M, Sarkar K, Sil S Med Oncol. 2024; 42(1):1.

PMID: 39532757 DOI: 10.1007/s12032-024-02553-9.

Investigating Potential Cancer Therapeutics: Insight into Histone Deacetylases (HDACs) Inhibitions.

Ahmad B, Saeed A, Al-Amery A, Celik I, Ahmed I, Yaseen M Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675404 PMC: 11054547. DOI: 10.3390/ph17040444.

References

Li Y, Seto E . HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016; 6(10). PMC: 5046688. DOI: 10.1101/cshperspect.a026831. View

Damaskos C, Garmpis N, Valsami S, Kontos M, Spartalis E, Kalampokas T . Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer. Anticancer Res. 2016; 37(1):35-46. DOI: 10.21873/anticanres.11286. View

Garmpis N, Damaskos C, Dimitroulis D, Kouraklis G, Garmpi A, Sarantis P . Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer. J Pers Med. 2022; 12(10). PMC: 9604828. DOI: 10.3390/jpm12101672. View

Archer S, Hodin R . Histone acetylation and cancer. Curr Opin Genet Dev. 1999; 9(2):171-4. DOI: 10.1016/s0959-437x(99)80026-4. View

Ropero S, Esteller M . The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2009; 1(1):19-25. PMC: 5543853. DOI: 10.1016/j.molonc.2007.01.001. View

Hu Z, Wei F, Su Y, Wang Y, Shen Y, Fang Y . Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression. Signal Transduct Target Ther. 2023; 8(1):11. PMC: 9816171. DOI: 10.1038/s41392-022-01221-6. View

Xu P, Xiong W, Lin Y, Fan L, Pan H, Li Y . Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression. Cell Death Dis. 2021; 12(8):779. PMC: 8349356. DOI: 10.1038/s41419-021-04047-2. View

Zhang Z, Qiu N, Yin J, Zhang J, Liu H, Guo W . SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression. Theranostics. 2020; 10(10):4290-4307. PMC: 7150493. DOI: 10.7150/thno.41008. View

Felsenfeld G . Chromatin as an essential part of the transcriptional mechanism. Nature. 1992; 355(6357):219-24. DOI: 10.1038/355219a0. View

10.

Dass S, Tan K, Selva Rajan R, Mokhtar N, Mohd Adzmi E, Wan Abdul Rahman W . Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities. Medicina (Kaunas). 2021; 57(1). PMC: 7826673. DOI: 10.3390/medicina57010062. View

11.

Davey C, Sargent D, Luger K, Maeder A, Richmond T . Solvent mediated interactions in the structure of the nucleosome core particle at 1.9 a resolution. J Mol Biol. 2002; 319(5):1097-113. DOI: 10.1016/S0022-2836(02)00386-8. View

12.

Xie Y, Shi Z, Qian Y, Jiang C, Liu W, Liu B . HDAC2- and EZH2-Mediated Histone Modifications Induce PDK1 Expression through miR-148a Downregulation in Breast Cancer Progression and Adriamycin Resistance. Cancers (Basel). 2022; 14(15). PMC: 9329997. DOI: 10.3390/cancers14153600. View

13.

Boyle P . Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012; 23 Suppl 6:vi7-12. DOI: 10.1093/annonc/mds187. View

14.

Psilopatis I, Garmpis N, Garmpi A, Vrettou K, Sarantis P, Koustas E . The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy. Cancers (Basel). 2023; 15(8). PMC: 10137219. DOI: 10.3390/cancers15082222. View

15.

Kim A, Mo K, Kwon H, Choe S, Park M, Kwak W . Epigenetic Regulation in Breast Cancer: Insights on Epidrugs. Epigenomes. 2023; 7(1). PMC: 9953240. DOI: 10.3390/epigenomes7010006. View

16.

Huang W, Chen J, Liu X, Liu X, Duan S, Chen L . MIER3 induces epithelial-mesenchymal transition and promotes breast cancer cell aggressiveness via forming a co-repressor complex with HDAC1/HDAC2/Snail. Exp Cell Res. 2021; 406(1):112722. DOI: 10.1016/j.yexcr.2021.112722. View

17.

Kouzarides T . Chromatin modifications and their function. Cell. 2007; 128(4):693-705. DOI: 10.1016/j.cell.2007.02.005. View

18.

Elias A . Triple-negative breast cancer: a short review. Am J Clin Oncol. 2009; 33(6):637-45. DOI: 10.1097/COC.0b013e3181b8afcf. View

19.

Grunstein M . Histone acetylation in chromatin structure and transcription. Nature. 1997; 389(6649):349-52. DOI: 10.1038/38664. View

20.

Marks P, Richon V, Rifkind R . Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000; 92(15):1210-6. DOI: 10.1093/jnci/92.15.1210. View